Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.79 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14934430 | 0.94 | EPHX2 (0.70) | EPHX2TRPV1USP2CYP1A2CYP3A4 | |
| SCHEMBL14934474 | 0.90 | EPHX2 (0.65) | EPHX2TRPV1USP2CYP1A2CYP3A4 | |
| SCHEMBL14934524 | 0.89 | EPHX2 (1.00) | EPHX2TRPV1 | |
| SCHEMBL14934435 | 0.86 | EPHX2 (0.64) | EPHX2TRPV1USP2CYP1A2CYP3A4 | |
| SCHEMBL14934568 | 0.86 | EPHX2 (0.63) | EPHX2TRPV1USP2CYP1A2CYP3A4 | |
| SCHEMBL14934408 | 0.86 | EPHX2 (0.63) | EPHX2TRPV1USP2CYP1A2CYP3A4 | |
| SCHEMBL14934575 | 0.82 | EPHX2 (0.66) | EPHX2TRPV1USP2CYP1A2CYP3A4 | |
| SCHEMBL14934571 | 0.81 | EPHX2 (0.64) | EPHX2TRPV1USP2CYP1A2CYP3A4 | |
| SCHEMBL14934434 | 0.81 | EPHX2 (0.59) | EPHX2TRPV1USP2CYP1A2CYP3A4 | |
| SCHEMBL14934396 | 0.81 | EPHX2 (0.64) | EPHX2USP2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013065712-A1 | DIAZASPIROUREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 東レ株式会社 (JP) | 2013-05-10 | — | — | WO | disclosed |